MaxLife Statement Regarding FDA Warning Letter 721453

Published: February 24, 2026 Last updated: August 31, 2026

MaxLife Technologies Inc. is providing this public update regarding the U.S. Food and Drug Administration warning letter dated February 20, 2026, the corrective actions undertaken in response, and the current public status of the matter.

On February 20, 2026, the FDA issued Warning Letter 721453 to MaxLife Technologies Inc. following FDA's review of certain content that appeared on MaxLife.com in December 2025. The letter addressed representations concerning compounded semaglutide and tirzepatide products, including certain product imagery, FDA-related language, and comparisons with FDA-approved products.

Following receipt of the warning letter, MaxLife conducted a review of the cited content and broader medication-related website materials. MaxLife revised website content and related promotional language to address the concerns described in the warning letter and has continued reviewing medication-related content as part of its compliance process.

Current status: As of August 28, 2026, FDA has not published a formal close-out letter for Warning Letter 721453. MaxLife therefore does not characterize the matter as closed, cleared, FDA-approved, or formally resolved by FDA.

FDA reference: MARCS-CMS 721453 Warning letter date: February 20, 2026 FDA source: FDA Warning Letter 721453 — MaxLife Technologies Inc. dba MaxLife

What FDA identified

FDA's warning letter addressed several categories of website representations. Among other things, FDA stated that certain content could:

  • Suggest that MaxLife itself was the entity compounding the medications.
  • Create the impression that compounded semaglutide or tirzepatide products were FDA-approved or had undergone FDA review for safety and effectiveness.
  • Suggest equivalence between compounded products and FDA-approved branded products.
  • Raise similar concerns beyond the specific examples cited in the letter.

The complete warning letter is available directly from FDA at fda.gov.

Corrective actions

MaxLife's remediation work has focused on making the roles of MaxLife, healthcare providers, pharmacy partners, compounded medications, and FDA-approved products clearer to consumers.

  1. Compounded-medication disclosures. MaxLife revised medication-related content to state that compounded medications are not FDA-approved and do not undergo FDA premarket review in the same manner as FDA-approved drugs.
  2. Clarification of MaxLife's role. MaxLife revised public materials to distinguish MaxLife's patient-management and technology role from the roles of independent licensed healthcare providers and dispensing or compounding pharmacy partners.
  3. Product imagery and labeling references. MaxLife reviewed medication imagery and related descriptions to reduce the risk of inaccurately identifying MaxLife as the manufacturer or compounding pharmacy.
  4. Separation of branded-drug evidence from compounded products. MaxLife revised the presentation of clinical-study and branded-product references so the product actually studied is identified and the surrounding context does not imply that a compounded product underwent the same FDA review or clinical testing.
  5. Broader claims review. MaxLife expanded review of medication pages, landing pages, advertising, email, SMS, social content, and other promotional materials for wording that could improperly imply FDA approval, generic equivalence, demonstrated clinical outcomes, or other unsupported claims.
  6. Prevention of recurrence. MaxLife continues to maintain and improve content-review procedures, approval workflows, restricted-claim guidance, supporting source records, and periodic review of prescription-medication content.

Compounded medications and FDA approval

Compounded medications are not FDA-approved. FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed in the same way it reviews FDA-approved drug products.

MaxLife's role

MaxLife Technologies Inc. operates a patient-management and technology platform that works with independent licensed healthcare providers and pharmacy partners. MaxLife is not represented on this page as the manufacturer or compounding pharmacy.

Ongoing compliance review

MaxLife continues to review website and promotional materials as its services evolve and as applicable regulatory guidance changes. This includes medication-related claims, pharmacy and provider descriptions, required disclosures, and the context in which clinical-study data are presented.

MaxLife also maintains documentation supporting corrective actions taken in response to Warning Letter 721453, including website records, applicable labeling or pharmacy information, content-review records, and other materials appropriate for regulatory review.

FDA close-out status

FDA explains that a warning-letter close-out may be issued after the agency evaluates a company's corrective actions and determines that the violations described in the warning letter have been adequately addressed. Corrective actions described by a company do not, by themselves, constitute an FDA close-out determination.

As of August 31, 2026, MaxLife has not identified a publicly posted FDA close-out letter for Warning Letter 721453. If FDA publishes a MaxLife response, close-out letter, or other material update regarding this matter, MaxLife intends to update this page and link directly to the relevant FDA record.